Zambia still imports roughly 70 – 90 percent of its essential medicines, yet domestic demand for pharmaceuticals is growing at double-digit rates. For foreign investors, this supply gap—combined with generous tax holidays inside Multi-Facility Economic Zones (MFEZs) and a streamlined licensing framework under the Zambia Medicines Regulatory Authority (ZAMRA)—creates a rare opportunity to build profitable, export-ready plants while strengthening the country’s health system.

1. Market Opportunity Snapshot

  • Rapid growth: Zambia’s pharma market is projected to expand by 13 – 14 % annually through 2026 and surpass US $300 million by 2030.

  • Import dependence: Only 7 licensed manufacturers operate locally; imports (mainly generics from India) still dominate shelves.

  • Regional reach: A plant in Lusaka can ship duty-free to eight neighbouring countries—a combined population of 450 million—under SADC and AfCFTA rules.

High-potential product lines

| Segment | Rationale | | Generic antiretrovirals & anti-malarials | Largest public-sector tenders; chronic demand | | Non-communicable disease drugs (diabetes, hypertension) | Rising lifestyle disease burden | | Medical consumables (syringes, gloves) | Low technical barrier, high import bill |

2. Navigating ZAMRA Licensing in Five Steps

  • Apply on the ZAMRA e-portal – upload incorporation papers, site master file, proof of fee payment.

  • Document screening – regulators confirm completeness and may request clarifications.

  • Pre-licensing GMP inspection – inspectors verify building design, HVAC, water systems, SOPs and staff credentials.

  • Licensing Committee review – findings presented; queries resolved.

  • Licence issuance – Director-General signs off; certificate is valid for one year and renewable.

Fast-track option: Local manufacturers enjoy an accelerated three-month review (versus 9-12 months for imports) if they submit dossiers in ICH-CTD format and meet WHO-GMP.

Core compliance must-haves

  • WHO-aligned Quality Management System (deviation control, CAPA, recalls).

  • At least one resident pharmacist registered with the Health Professions Council.

  • Valid Environmental Impact Assessment (EIA) clearance.

  • Secure electronic batch-record archive (minimum ten-year retention).

3. Why Build Inside an MFEZ?

| Incentive | Years 1-10 | Years 11-13 | Years 14-15 | | Corporate tax on export profits | 0 % | 50 % of standard rate | 75 % | | Dividend tax | 0 % (first 10 yrs) | Standard | Standard | | Duty on capital equipment | 0 % (first 5 yrs) | Standard | Standard |

Additional perks include free immigration-permit facilitation, subsidised electricity and water connections, internal road and ICT networks, and on-site one-stop shops for secondary licences. The Lusaka South MFEZ already hosts NRB Pharma and Mylan Laboratories, demonstrating proof of concept.

4. Unlocking Multi-Country Registration with ZAZIBONA

The ZAZIBONA collaborative procedure (Zambia, Zimbabwe, Botswana, Namibia + 5 other SADC states) lets firms submit one CTD dossier and gain marketing authorisations across nine markets in 6–8 months. Average review costs hover around US $4,500 per product—a fraction of filing separately. Focus on essential medicines or WHO-prequalified products to maximise approval odds.

5. Success Case: NRB Pharma Zambia Ltd

  • Investment: US $10 million green-field plant, Lusaka South MFEZ.

  • Outcome: First WHO-certified facility in Zambia; won a 15 % price preference in government tenders.

  • Regulatory timeline: 3-month fast-track licence + ZAZIBONA clearance allowed exports within Year 1.

6. Risk Landscape & Mitigation

| Challenge | Impact | Mitigation | | Regulatory learning curve | Delays, extra cost | Hire local regulatory consultants; pre-audit plant to WHO-GMP | | Raw-material import dependence | FX exposure, stock-outs | Diversify suppliers within SADC/COMESA; maintain safety stock | | Power & water reliability | Production downtime | Locate in MFEZ; budget for rooftop solar + back-up borehole | | Competitive pricing pressure | Margin squeeze | Automate QC, leverage tax holidays, specialise in chronic-disease lines |

7. Strategic Roadmap for New Entrants

  • Choose your zone: Compare lease rates and utility tariffs across Lusaka South, Chambishi and ZCCZ.

  • Lock in incentives early: Sign an Investment Promotion & Protection Agreement (IPPA) with the Zambia Development Agency to guarantee tax terms.

  • Design for GMP from day one: Engage an EPC contractor experienced in clean-room builds.

  • File ZAMRA & ZAZIBONA dossiers in parallel to compress time-to-market.

  • Partner locally: Equity or contract-manufacturing deals with existing distributors ease public-sector tender access.

  • Plan regional logistics: Use Lusaka airport cargo hub and Tazara rail links to reach DRC, Tanzania and Malawi.

Conclusion

With a widening medicine gap, a government eager to localise production, decade-long tax holidays and a harmonised regional registration pathway, Zambia has become one of Southern Africa’s most attractive frontiers for pharmaceutical manufacturing investment. By anchoring operations inside an MFEZ, adhering strictly to ZAMRA’s fast-track GMP standards and structuring supply chains for SADC reach, foreign investors can achieve both commercial success and lasting impact on public health.